B Dahlof

Summary

Country: Sweden

Publications

  1. ncbi request reprint Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
    Bjorn Dahlof
    Sahlgrenska University Hospital Ostra, Gothenburg, Swede
    Lancet 359:995-1003. 2002
  2. ncbi request reprint Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond
    B Dahlof
    Goteborg University, Goteborg, Sweden
    J Renin Angiotensin Aldosterone Syst 1:S14-6. 2000
  3. ncbi request reprint The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group
    B Dahlof
    Ostra University Hospital, Goteborg, Sweden
    Am J Hypertens 10:705-13. 1997
  4. ncbi request reprint Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    B Dahlof
    Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 18:367-73. 2004
  5. ncbi request reprint Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Goteborg, Sweden
    Am J Hypertens 5:95-110. 1992
  6. doi request reprint Management of cardiovascular risk with RAS inhibitor/CCB combination therapy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 23:77-85. 2009
  7. ncbi request reprint Left ventricular hypertrophy and angiotensin II antagonists
    B Dahlof
    Clinical Experimental Research Laboratory, Sahlgrenska University Hospital, Ostra, Goteborg, Sweden
    Am J Hypertens 14:174-82. 2001
  8. ncbi request reprint Further evidence for low-dose combinations in patients with left ventricular hypertrophy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 19:S9-14. 2005

Detail Information

Publications8

  1. ncbi request reprint Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
    Bjorn Dahlof
    Sahlgrenska University Hospital Ostra, Gothenburg, Swede
    Lancet 359:995-1003. 2002
    ..We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death...
  2. ncbi request reprint Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond
    B Dahlof
    Goteborg University, Goteborg, Sweden
    J Renin Angiotensin Aldosterone Syst 1:S14-6. 2000
    ..This drug may provide additional benefits in controlling the cardiovascular complications of hypertension. Results of large clinical trials with valsartan, such as VALUE, Val-HEFT, VALIANT and ABCD-2V, are eagerly awaited...
  3. ncbi request reprint The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group
    B Dahlof
    Ostra University Hospital, Goteborg, Sweden
    Am J Hypertens 10:705-13. 1997
    ..On April 30, 1997, when inclusion was stopped, 9,218 patients had been randomized...
  4. ncbi request reprint Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    B Dahlof
    Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 18:367-73. 2004
    ..5-year period. A population-wide prevention strategy of using losartan in patients with LVH and hypertension has the potential to have a major public health impact by reducing the morbidity and mortality of stroke in the EU...
  5. ncbi request reprint Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Goteborg, Sweden
    Am J Hypertens 5:95-110. 1992
    ..However, this theory and its possible prognostic implications need to be evaluated in controlled prospective trials...
  6. doi request reprint Management of cardiovascular risk with RAS inhibitor/CCB combination therapy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 23:77-85. 2009
    ..Meanwhile, such a combination offers effective, convenient, well-tolerated control of the most important modifiable risk factor for CVD...
  7. ncbi request reprint Left ventricular hypertrophy and angiotensin II antagonists
    B Dahlof
    Clinical Experimental Research Laboratory, Sahlgrenska University Hospital, Ostra, Goteborg, Sweden
    Am J Hypertens 14:174-82. 2001
    ..Published data include open-label and randomized studies with losartan treatment for left ventricular hypertrophy, with fewer studies investigating the effects of valsartan, irbesartan, and candesartan...
  8. ncbi request reprint Further evidence for low-dose combinations in patients with left ventricular hypertrophy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 19:S9-14. 2005
    ..This reduction cannot be entirely explained by the better efficacy of the low-dose combination on blood pressure reduction...